Predictive proteomic biomarkers for inflammatory bowel disease-associated cancer: Where are we now in the era of the next generation proteomics?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jong-Min | - |
dc.contributor.author | Han, Na Young | - |
dc.contributor.author | Han, Young-Min | - |
dc.contributor.author | Chung, Mi Kyung | - |
dc.contributor.author | Lee, Hoo Keun | - |
dc.contributor.author | Ko, Kwang Hyun | - |
dc.contributor.author | Kim, Eun-Hee | - |
dc.contributor.author | Hahm, Ki Baik | - |
dc.date.available | 2020-02-28T15:45:55Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-10-07 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12185 | - |
dc.description.abstract | Recent advances in genomic medicine have opened up the possibility of tailored medicine that may eventually replace traditional "one-size-fits all" approaches to the treatment of inflammatory bowel disease (IBD). In addition to exploring the interactions between hosts and microbes, referred to as the microbiome, a variety of strategies that can be tailored to an individual in the coming era of personalized medicine in the treatment of IBD are being investigated. These include prompt genomic screening of patients at risk of developing IBD, the utility of molecular discrimination of IBD subtypes among patients diagnosed with IBD, and the discovery of proteome biomarkers to diagnose or predict cancer risks. Host genetic factors influence the etiology of IBD, as do microbial ecosystems in the human bowel, which are not uniform, but instead represent many different microhabitats that can be influenced by diet and might affect processes essential to bowel metabolism. Further advances in basic research regarding intestinal inflammation may reveal new insights into the role of inflammatory mediators, referred to as the inflammasome, and the macromolecular complex of metabolites formed by intestinal bacteria. Collectively, knowledge of the inflammasome and metagenomics will lead to the development of biomarkers for IBD that target specific pathogenic mechanisms involved in the spontaneous progress of IBD. In this review article, our recent results regarding the discovery of potential proteomic biomarkers using a label-free quantification technique are introduced and on-going projects contributing to either the discrimination of IBD subtypes or to the prediction of cancer risks are accompanied by updated information from IBD biomarker research. (C) 2014 Baishideng Publishing Group Inc. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BAISHIDENG PUBLISHING GROUP INC | - |
dc.relation.isPartOf | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.subject | UDP-GLUCOSE DEHYDROGENASE | - |
dc.subject | COLORECTAL NEOPLASIA RISK | - |
dc.subject | FLIGHT MASS-SPECTROMETRY | - |
dc.subject | INTESTINAL INFLAMMATION | - |
dc.subject | NONNEOPLASTIC EPITHELIUM | - |
dc.subject | INCREASED EXPRESSION | - |
dc.subject | FECAL LACTOFERRIN | - |
dc.subject | CARCINOGENESIS | - |
dc.subject | IDENTIFICATION | - |
dc.subject | MARKERS | - |
dc.title | Predictive proteomic biomarkers for inflammatory bowel disease-associated cancer: Where are we now in the era of the next generation proteomics? | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000343881200021 | - |
dc.identifier.doi | 10.3748/wjg.v20.i37.13466 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF GASTROENTEROLOGY, v.20, no.37, pp.13466 - 13476 | - |
dc.identifier.scopusid | 2-s2.0-84910001597 | - |
dc.citation.endPage | 13476 | - |
dc.citation.startPage | 13466 | - |
dc.citation.title | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.volume | 20 | - |
dc.citation.number | 37 | - |
dc.contributor.affiliatedAuthor | Han, Na Young | - |
dc.contributor.affiliatedAuthor | Lee, Hoo Keun | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Inflammatory bowel disease | - |
dc.subject.keywordAuthor | Biomarker | - |
dc.subject.keywordAuthor | Proteomics | - |
dc.subject.keywordAuthor | Tailored medicine | - |
dc.subject.keywordAuthor | Colitic cancer | - |
dc.subject.keywordPlus | UDP-GLUCOSE DEHYDROGENASE | - |
dc.subject.keywordPlus | COLORECTAL NEOPLASIA RISK | - |
dc.subject.keywordPlus | FLIGHT MASS-SPECTROMETRY | - |
dc.subject.keywordPlus | INTESTINAL INFLAMMATION | - |
dc.subject.keywordPlus | NONNEOPLASTIC EPITHELIUM | - |
dc.subject.keywordPlus | INCREASED EXPRESSION | - |
dc.subject.keywordPlus | FECAL LACTOFERRIN | - |
dc.subject.keywordPlus | CARCINOGENESIS | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | MARKERS | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.